EDITION:
- EU
- NA
As Europe’s medical cannabis market shifts from a focus on growth to pharmaceutical discipline, PHCANN International has emerged as a
This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical When Donald Trump tweets, the world pays
In the latest instalment of our series spotlighting expert contributors to Prohibition Partners’ newly launched Insights Hub, we spoke with
In the latest instalment of our series spotlighting the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat
There is a frustrating misimpression circulating in the cannabis community regarding rescheduling. Many headlines state that Trump is considering finishing
In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
As the UK’s medical cannabis patient population pushes past an estimated 60,000, questions about market maturity, patient access, and regulatory
A new phase of cannabis enforcement is underway—and few in the industry are prepared. In this guest post, activist and cannabis business and political consultant Deb Tharp lays out a compelling case that recent raids, regulatory pivots, and conservative policy blueprints like Project 2025 are not isolated events but part of a broader, coordinated shift. Her warning to operators? The trap has already been set.
Most people associate the Isle of Man with its world-famous TT motorcycle races or its well-established financial services sector. But quietly and confidently, our Island is taking bold steps towards building one of Europe’s most exciting and high-potential new industries: medicinal cannabis.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
